Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vellas, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vellas, B.
NEUROLOGY 2006;67:S6-S11
© 2006 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

The GuidAge study

Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761® for prevention of Alzheimer disease in patients over 70 with a memory complaint B. Vellas, MD, S. Andrieu, MD, P. J. Ousset, MD, M. Ouzid, MD, H. Mathiex-Fortunet, MD for the GuidAge Study Group*

INSERM (French National Institute of Health and Medical Research), U558, F-31073 Toulouse, France; University Toulouse III, Toulouse, France (Dr. Vellas, Dr. Andrieu, Dr. Ousset); CHU Toulouse, Hôpital Casselardit, Service of internal medicine and clinical gerontology, Toulouse, France (Dr. Vellas, Dr. Ousset); CHU Toulouse, Service of epidemiology and public health, Toulouse, F-31073 France (Dr. Andrieu); IPSEN, Paris, France (Dr. Ouzid, Dr. Mathiex-Fortunet).

Address correspondence to: Pr B Vellas, Hôpital Casselardit, Service de médecine interne et gérontologie clinique, 170 avenue de Casselardit, 3100 Toulouse, France, email: vellas.b{at}chu-toulouse.fr

Background: Preventive approaches in the field of Alzheimer disease (AD) is important but these trials raise many questions. Which protective factor should be studied? What population should be studied? With which principal and secondary criteria? We present here the design of the ongoing GuidAge Study. In the past, several studies suggest that Ginkgo biloba could have a potential benefit effect on cognitive function. The aim of the GuidAge Study is to evaluate the efficacy of 240 mg/d of EGb 761® in the prevention of AD.

Methods: GuidAge is a 5-year double-blind randomized trial conducted in France by a private practice/hospital network of general practitioners and hospital practitioners specializing in memory disorders. This study enrolled elderly subjects with spontaneous memory complaint and the primary outcome is the incidence of AD during a 5 years follow-up period. A total of 2854 subjects were enrolled between March 2002 and September 2004. The age of the study population was 76.8 ± 4.4 with mean MMSE at entry 27.8 ± 1.7.

Conclusion: The GuidAge study is the largest study carried out in Europe on the prevention of AD. Final results should be available in 2010.

*See the Appendix for a list of GuidAge Study Group members

Publication of this supplement was supported by an educational grant from Beaufour Ipsen.

Disclosure: The sponsor has provided B.V. with an honorarium for his participation in this project, honorarium during his career, and grant support.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. Kaye
Ginkgo biloba Prevention Trials: More Than an Ounce of Prevention Learned
Arch Neurol, May 1, 2009; 66(5): 652 - 654.
[Full Text] [PDF]

Home page
 JAMAHome page
S. T. DeKosky, J. D. Williamson, A. L. Fitzpatrick, R. A. Kronmal, D. G. Ives, J. A. Saxton, O. L. Lopez, G. Burke, M. C. Carlson, L. P. Fried, et al.
Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial
JAMA, November 19, 2008; 300(19): 2253 - 2262.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand
Dementia Prevention: Methodological Explanations for Inconsistent Results
Epidemiol. Rev., November 1, 2008; 30(1): 35 - 66.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
H. H. Dodge, T. Zitzelberger, B. S. Oken, D. Howieson, and J. Kaye
A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline
Neurology, May 6, 2008; 70(19_Part_2): 1809 - 1817.
[Abstract] [Full Text] [PDF]